News

The double-blind, placebo controlled trial, being conducted at 15 sites in the US, is a dose response study comparing 400mg and 600mg of Droxidopa to placebo in a

Rosetta Genomics has developed a custom designed, highly sensitive and specific microRNA detection platform which is based on Roche PCR technology. This proprietary platform is said to help

VIA-2291 is a potent small molecule drug that targets inflammation in the blood vessel wall, a primary disease process in atherosclerosis. The Phase II clinical program’s innovative trial

Based in Lexington, Kentucky, LevTech will be combined with ATMI’s existing LifeSciences business focused on single-use bioprocess containers and processes for the biopharmaceutical industry. Doug Neugold, CEO of

If the non-radiolabeled TM601 receives FDA approval for malignant glioma, it will entitle TransMolecular to exclusive marketing rights for the compound for the treatment of malignant glioma for

Through the collaboration, Centocor will support the discovery research and preclinical development by Catalyst of Alterase drug candidates against two targets, one of which is in inflammatory disease,

This one-year extension of the research phase of the agreement will result in NicOx receiving E3 million in research funding in March 2008. Under the terms of the

According to Specialty Blades, the acquisition of Popper makes the combined company the leading contract manufacturer of cutting and piercing devices for the medical device industry. The combined

The company said that preliminary results confirm the good tolerability profile of EVT 302 and are an encouraging basis for further clinical development. EVT 302 was investigated in